Acamprosate (Campral®) is approved for the treatment of alcoholism in the U.S. and Europe. It presumably blocks excitatory glutamatergic
N-methyl-d-aspartate (NMDA) receptors (
59–
61) while enhancing γ-aminobutyric acid (GABA)-mediated nerve inhibition (
62–
64). However, some studies indicate that acamprosate enhances NMDA function, while others indicate that the compound enhances NMDA-induced excitability at low concentrations and suppresses it at high concentrations (
62–
65). Other reports suggest that acamprosate has no effect on GABA-mediated currents (
66), and some reports suggest that acamprosate inhibits the binding of taurine to taurine receptors (
67).
One paper has been published on the use of acamprosate to treat tinnitus patients, most of whom had mild to profound noise-induced hearing loss (
68,
69). The rationale for treatment assumes that tinnitus arises from excess glutamatergic activity through NMDA receptors and/or hyperactivity resulting from the loss of GABA-mediated inhibition (
70–
75). In this double-blind study, patients received placebo or acamprosate (333 mg t.i.d.) and rated the loudness and annoyance of their tinnitus before and at monthly intervals of treatment. Acamprosate had no beneficial effects after 30 days of treatment, a modest benefit at 60 days and a significant effect at 90 days. Approximately 87% of the subjects in the acamprosate group showed some improvement, including three subjects in whom tinnitus disappeared, compared to 44% in the placebo group. A larger clinical trial is currently under way to further assess the encouraging results from this preliminary study (
http://clinicaltrials.gov/ct2/show/NCT00596531).
Is there anyone that have try CAMPRAL 666mg x3 daily for three months?!
Member
and clonazepam cause you Tinnitus.
